<a href="https://laohu8.com/S/ALZN">Alzamend Neuro</a> Inc. Reports No Revenue, Net Loss Narrows by 49.9%, EPS Improves by $121.27
Alzamend Neuro Inc. released its financial results for the fiscal year ending April 30, 2025. The company reported a net loss attributable to common shares of approximately $4.99 million, a decrease from the previous year's net loss of about $9.95 million, reflecting a 49.9% improvement. Total operating expenses were $4.50 million, down 55% from $9.94 million the prior year. Research and development expenses significantly decreased by 78% to $1.41 million from $6.46 million, while general and administrative expenses also saw a reduction of 12% to $3.08 million from $3.48 million. The company's product candidates, AL001 and ALZN002, remain in the clinical stage of development, requiring further study, evaluation, and regulatory approval before generating revenue. Alzamend Neuro Inc. continues to advance the clinical development of AL001 for the treatment of Alzheimer's, BD, MDD, and PTSD, as well as ALZN002 for Alzheimer's treatment. The company is also focused on expanding its pipeline of pharmaceuticals to include additional indications and delivery methods for AL001.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001214659-25-010763), on July 22, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.